Meretek at PriMed Southwest
LAFAYETTE, Colo., Jan. 22 /PRNewswire/ — Meretek Diagnostics, manufacturer of the BreathTek(TM) UBT kit for the bacterium Helicobacter pylori (H. pylori), will be exhibiting at the PriMed Southwest show January 25-27, 2007, at the George R. Brown Convention Center in Houston, Texas.
Meretek is demonstrating its BreathTek(TM) UBT (urea breath test) in booth #350. BreathTek(TM) UBT tests for active H. pylori infection, which is commonly associated with peptic ulcers. It can be administered and results returned in a matter of minutes through a physician’s office or participating laboratory.
“Awareness is really important when it comes to managing dyspepsia and peptic ulcers,” said David Walton, Vice President for Sales. “We’re letting physicians, distributors and laboratories know that this patient friendly test is widely available to aid in initial diagnosis and to confirm eradication following treatment.”
Approximately 1 in 3 adults in the U.S. is infected with H. pylori, one in ten may develop a peptic ulcer over their lifetime and 80 to 90 percent of peptic ulcers are caused by an H. pylori infection. However, what is most frustrating is how inaccurate diagnosis and treatment of dyspepsia remains in the primary care setting — more than 10 years after clinical guidelines have been issued and disseminated.
The BreathTek(TM) UBT is a simple, non-radioactive, non-invasive, 95 percent sensitive and specific solution to diagnose and monitor treatment of active H. pylori infection. Despite continued use, antibody-based blood tests can not distinguish between an active and past infection. Since H. pylori is contagious and a class-one carcinogen, it’s important for patients and physicians to accurately identify and treat an active infection.
The BreathTek UBT is CLIA non-regulated, covered by Medicare and most major insurance carriers. For a complete listing of features and benefits of the BreathTek UBT, visit http://www.meretek.com/physician_testing.asp.
Meretek products also include the UBiT(R)-IR300 infrared spectrophotometer and the POCone(TM) infrared spectrophotometer instruments which are used to analyze the patient’s breath samples.
Look for Meretek at these upcoming shows PriMed South, Feb 23 -25 in Ft. Lauderdale, FL., and ACOFP March 14-16 in Kissimmee, FL.
About Meretek Diagnostics
Located in Lafayette, Colo., Meretek Diagnostics Inc. is a subsidiary of Otsuka America, a healthcare company engaged in the development of advanced, non-invasive, non-radioactive breath tests and instrumentation. Meretek was founded in 1993 by a group from the Baylor College of Medicine in Houston, Texas. The company holds exclusive licenses to patents involving the 13C urea breath test technologies, and all of the their products are approved by the FDA.
For more information about Meretek Diagnostics, Inc. and the company’s products, including prescribing information, warnings and limitations, visit the Meretek Web site at http://www.meretek.com/.
Meretek Diagnostics, Inc.
CONTACT: Dan Snyders, ext. 230, email@example.com, or JenniferHanson, ext. 239, firstname.lastname@example.org, both of Armada MedicalMarketing, +1-303-623-1190, for Meretek
Web site: http://www.meretek.com/